Prior to COVID-19, the U.S. was in the midst of a different epidemic, with nearly 130 people a day dying of an opioid overdose. Individuals with substance use disorders (SUDs) are particularly vulnerable during the COVID-19 pandemic, and the systems of care upon which they rely have been severely constrained. In response, some regulatory policies have been eased and treatment programs have adapted. Our panel of experts will explore the policy and public health implications of the twin epidemics of COVID-19 and opioids, and examine questions such as: In what ways do the populations most affected by COVID-19 and the opioid crisis overlap? How have social distancing and shelter-in-place policies affected access to care for SUD patients? What challenges does COVID-19 pose to SUD treatment and recovery more generally, and what policy levers can we use to address them?
Zachary Meisel, MD, MPH, MSHP Director, Center for Emergency Care Policy Research; Associate Professor, Emergency Medicine, Perelman School of Medicine
Yngvild Olsen, MD, MPH, DFASAM Medical Director, Institutes for Behavior Resources Inc/REACH Health Services; Vice President, American Society of Addiction Medicine
Joshua Sharfstein, MD Vice Dean, Public Health Practice and Community Engagement and Professor, Health Policy & Management, Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health